Search

Copyright of Tunnel Construction / Suidao Jianshe (Zhong-Yingwen Ban) is the property of Tunnel Construction Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effect of paclitaxel combined with rapamycin on the STAT3 expression in patients with endometrial carcinoma. Methods: 90 patients with endometrial carcinom a who were treated in our hospital were selected and randomly divided into the control group and the experiment group. The patients in the control group were treated with conventional chemotherapy, while the patients in the experiment group were treated with paclitaxel and rapamycin. Then the cell growth inhibition rate and the changes of the interferon, the growth factor, the interleukin and STAT3 in the two groups were observed and compared before and after the treatment Results: Compared with before treatment the cell growth inhibition rate and the expression levels of the growth factor, the interleukin and the STAT3 in the two groups decreased, and the levels of the interferon increased, and the differences were statistically significant (P<0.05); Compared with the control group after treatment, the cell growth inhibition rate and the expressions of the growth factor, the interleukin and the STAT3 in the experiment group were lower, and the level of the interferon was higher, and the differences were statistically significant (P<0.05). Conclusion: Rapamycin combined with paclitaxel can improve the immune function and the activity of immune cells, enhance the malignant proliferation of cells that blocked mitosis process with significant efficacy, which is worthy of clinical application. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effect of cisplatin on the expression of PI3K/AKT and apoptosis related regulation factors in patients with ovarian cancer. Methods: 60 cases with ovarian cancer who were treated in our hospital were selected and randomly divided into the experiment and the control group, with 30 cases in each group. The patients in the control group were treated with cisplatin chemotherapy, while the patients in the experiment group were treated with the hyperthermia for 3 weeks. Then the changes of PI3 K, AKT and CA125 and the clinical efficacy of patients in the two groups were detected and compared before and after the treatment.Results: Compared with before treatment, the levels of PI3K, Akt and CA125 in the two groups decreased after the treatment, and the differences were statistically significant (P<0.05); Compared with the control group, the levels of PI3K, Akt and CA125 in the experiment group were lower after the treatment, and the differences were statistically significant (P<0.05); The total clinical efficiency of the experiment group was 80.0%, which was higher than 70.0%in the control group, and the difference was statistically significant (P<0.05).Conclusion: Compared with the simple application of cisplatin, the combination of the cisplatin chemotherapy and hyperthermia can reduce the levels of PI3 K, AKT and CA125 in patients with ovarian cancer, and improve the clinical efficacy, which is worthy of clinical significance. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Kunming Medical University / Kunming Yike Daxue Xuebao is the property of Kunming Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)